Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission?

  • Macedo, Filipa (Portuguese Oncology Institute - Coimbra) ;
  • Ladeira, Katia (Portuguese Oncology Institute - Lisbon) ;
  • Longatto-Filho, Adhemar (Life and Health Science Research Institute, School of Health Sciences, University of Minho) ;
  • Martins, Sandra F. (Life and Health Science Research Institute, School of Health Sciences, University of Minho)
  • Received : 2017.01.29
  • Accepted : 2017.03.03
  • Published : 2017.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Gastric cancer (GC) has high mortality owing to its aggressive nature. Tumor angiogenesis plays an essential role in the growth, invasion, and metastatic spread of GC. The aim of this work was to review the angiogenic biomarkers related to the behavior of GC, documented in the literature. A search of the PubMed database was conducted with the MeSH terms: "Stomach neoplasms/blood [MeSH] or stomach neoplasms/blood supply [MeSH] and angiogenic proteins/blood [Major]". A total of 30 articles were initially collected, and 4 were subsequently excluded. Among the 26 articles collected, 16 examined the role of vascular endothelial growth factor (VEGF), 4 studied endostatin, 3 investigated angiopoietin (Ang)-2, 2 studied the Ang-like protein 2 (ANGTPL2), and 1 each examined interleukin (IL)-12, IL-8, and hypoxia inducible factor. Regarding VEGF, 6 articles concluded that the protein was related to lymph node metastasis or distant metastases. Five articles concluded that VEGF levels were elevated in the presence of GC and decreased following tumor regression, suggesting that VEGF levels could be a predictor of recurrence. Four articles concluded that high VEGF levels were correlated with poor prognosis and lower survival rates. Ang-2 and ANGTPL2 were elevated in GC and associated with more aggressive disease. Endostatin was associated with intestinal GC. VEGF is the most extensively studied angiogenic factor. It is associated with the presence of neoplastic disease and lymph node metastasis. It appears to be a good biomarker for disease progression and remission, but not for diagnosis. The data regarding other biomarkers are inconclusive.

Keywords

References

  1. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014;50:1330-1344. https://doi.org/10.1016/j.ejca.2014.01.029
  2. Xie K, Huang S. Regulation of cancer metastasis by stress pathways. Clin Exp Metastasis 2003;20:31-43. https://doi.org/10.1023/A:1022590402748
  3. Villarejo-Campos P, Padilla-Valverde D, Martin RM, Menendez-Sanchez P, Cubo-Cintas T, Bondia-Navarro JA, et al. Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer. Clin Transl Oncol 2013;15:265-270. https://doi.org/10.1007/s12094-012-0908-x
  4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186. https://doi.org/10.1056/NEJM197111182852108
  5. Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol 2010;222:249-260. https://doi.org/10.1002/path.2760
  6. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013;328:18-26. https://doi.org/10.1016/j.canlet.2012.08.018
  7. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60. https://doi.org/10.1126/science.277.5322.55
  8. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001;181:16-19. https://doi.org/10.1016/S0002-9610(00)00549-3
  9. Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2010;2:125-148. https://doi.org/10.1177/1758834009360519
  10. Wang TB, Wang J, Wei XQ, Wei B, Dong WG. Serum vascular endothelial growth factor-C combined with multi-detector CT in the preoperative diagnosis of lymph node metastasis of gastric cancer. Asia Pac J Clin Oncol 2012;8:180-186. https://doi.org/10.1111/j.1743-7563.2011.01490.x
  11. Tsirlis TD, Kostakis A, Papastratis G, Masselou K, Vlachos I, Papachristodoulou A, et al. Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer. J Surg Oncol 2010;102:699-703. https://doi.org/10.1002/jso.21677
  12. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005;65:4739-4746. https://doi.org/10.1158/0008-5472.CAN-04-4576
  13. Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007;13:1794-1797. https://doi.org/10.3748/wjg.v13.i12.1794
  14. Kikuchi S, Obata Y, Yagyu K, Lin Y, Nakajima T, Kobayashi O, et al. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients. Cancer Sci 2011;102:866-869. https://doi.org/10.1111/j.1349-7006.2011.01860.x
  15. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998;80:171-175. https://doi.org/10.1055/s-0037-1615158
  16. Seo HY, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, et al. Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol 2010;40:1147-1153. https://doi.org/10.1093/jjco/hyq111
  17. Sheng SL, Bao SH, Huang G, Wang LM. Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours. Clin Exp Immunol 2008;151:459-466. https://doi.org/10.1111/j.1365-2249.2007.03548.x
  18. Ding S, Lin S, Dong X, Yang X, Qu H, Huang S, et al. Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer. In Vivo 2005;19:793-795.
  19. Park J, Seo AN, Yoon C, Ku GY, Coit DG, Strong VE, et al. Serum VEGF-A and tumor vessel VEGFR-2 levels predict survival in caucasian but not Asian patients undergoing resection for gastric adenocarcinoma. Ann Surg Oncol 2015;22 Suppl 3:S1508-S1515. https://doi.org/10.1245/s10434-015-4790-y
  20. Vidal O, Metges JP, Elizalde I, Valentini M, Volant A, Molina R, et al. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 2009;96:1443-1451. https://doi.org/10.1002/bjs.6780
  21. Bilgic CI, Tez M. Serum VEGF levels in gastric cancer patients: correlation with clinicopathological parameters. Turk J Med Sci 2015;45:112-117. https://doi.org/10.3906/sag-1401-154
  22. Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004;10:1115-1120. https://doi.org/10.3748/wjg.v10.i8.1115
  23. Masiak W, Szponar A, Chodorowska G, Dabrowski A, Pedowski T, Wallner G. Evaluation of endostatin and EGF serum levels in patients with gastric cancer. Pol Przegl Chir 2011;83:42-47.
  24. Wang ZH, Zhu ZT, Xiao XY, Sun J. Correlation of serum levels of endostatin with tumor stage in gastric cancer: a systematic review and meta-analysis. Biomed Res Int 2015;2015:623939.
  25. Koc M, Gocmen E, Kilic M, Ozbay M, Oktem M, Tez M. Serum endostatin levels in gastric cancer patients: correlation with clinicopathological parameters. Hepatogastroenterology 2006;53:616-618.
  26. Woo IS, Kim KA, Jeon HM, Hong SH, Rho SY, Koh SJ, et al. Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma. Int J Cancer 2006;119:2901-2906. https://doi.org/10.1002/ijc.22216
  27. Engin H, Ustundag Y, Ozel Tekin I, Gokmen A. Plasma concentrations of Ang-1, Ang-2 and Tie-2 in gastric cancer. Eur Cytokine Netw 2012;23:21-24.
  28. Jo MJ, Lee JH, Nam BH, Kook MC, Ryu KW, Choi IJ, et al. Preoperative serum angiopoietin-2 levels correlate with lymph node status in patients with early gastric cancer. Ann Surg Oncol 2009;16:2052-2057. https://doi.org/10.1245/s10434-009-0474-9
  29. Yoshinaga T, Shigemitsu T, Nishimata H, Takei T, Yoshida M. Angiopoietin-like protein 2 is a potential biomarker for gastric cancer. Mol Med Rep 2015;11:2653-2658. https://doi.org/10.3892/mmr.2014.3040
  30. Toiyama Y, Tanaka K, Kitajima T, Shimura T, Imaoka H, Mori K, et al. Serum angiopoietin-like protein 2 as a potential biomarker for diagnosis, early recurrence and prognosis in gastric cancer patients. Carcinogenesis 2015;36:1474-1483.
  31. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-586. https://doi.org/10.1093/jnci/87.8.581
  32. Nakayama Y, Inoue Y, Nagashima N, Katsuki T, Matsumoto K, Shibao K, et al. Relationships between local and systemic expression of interleukin-12 and plasma levels of vascular endothelial growth factor in patients with gastric cancer. Anticancer Res 2004;24:3289-3294.
  33. Konno H, Ohta M, Baba M, Suzuki S, Nakamura S. The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci 2003;94:735-740. https://doi.org/10.1111/j.1349-7006.2003.tb01511.x
  34. Blank S, Deck C, Dreikhausen L, Weichert W, Giese N, Falk C, et al. Angiogenic and growth factors in gastric cancer. J Surg Res 2015;194:420-429. https://doi.org/10.1016/j.jss.2014.11.028
  35. Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, et al. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Ann Surg Oncol 2014;21:1130-1137. https://doi.org/10.1245/s10434-013-3429-0
  36. Gao ZL, Zhang C, Du GY, Lu ZJ. Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma. Hepatogastroenterology 2007;54:1591-1595.
  37. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001;61:6548-6554.
  38. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91. https://doi.org/10.1038/379088a0
  39. Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, et al. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008;8:123. https://doi.org/10.1186/1471-2407-8-123

Cited by

  1. Interplay between TGF-β signaling and receptor tyrosine kinases in tumor development vol.60, pp.10, 2017, https://doi.org/10.1007/s11427-017-9173-5
  2. A New Role for Helicobacter pylori Urease: Contributions to Angiogenesis vol.8, pp.None, 2017, https://doi.org/10.3389/fmicb.2017.01883
  3. Probe-based confocal laser endomicroscopy for in vivo evaluation of the tumor vasculature in gastric and rectal carcinomas vol.7, pp.None, 2017, https://doi.org/10.1038/s41598-017-10963-1
  4. Establishment of a Model of Microencapsulated SGC7901 Human Gastric Carcinoma Cells Cocultured with Tumor-Associated Macrophages vol.2018, pp.None, 2017, https://doi.org/10.1155/2018/3767482
  5. Current understanding and management of Helicobacter pylori infection: an updated appraisal vol.7, pp.None, 2017, https://doi.org/10.12688/f1000research.14149.1
  6. Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression vol.23, pp.1, 2017, https://doi.org/10.3233/cbm-181287
  7. Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer vol.19, pp.1, 2017, https://doi.org/10.3390/ijms19010043
  8. New therapeutic options opened by the molecular classification of gastric cancer vol.24, pp.18, 2017, https://doi.org/10.3748/wjg.v24.i18.1942
  9. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer vol.19, pp.5, 2018, https://doi.org/10.3390/ijms19051477
  10. VEGFA and VEGFR2 RNAscope determination in gastric cancer vol.49, pp.4, 2018, https://doi.org/10.1007/s10735-018-9777-0
  11. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies vol.19, pp.13, 2017, https://doi.org/10.2217/pgs-2018-0077
  12. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects vol.84, pp.10, 2017, https://doi.org/10.1111/bcp.13691
  13. Combination of apatinib and continuous nutritional support for a gastric cancer patient with brain metastasis prolongs survival vol.43, pp.5, 2017, https://doi.org/10.1111/jcpt.12708
  14. Celastrus Orbiculatus Extract Suppresses Migration and Invasion of Gastric Cancer by Inhibiting Prohibitin and c-Raf/ERK Signaling Pathway vol.15, pp.1, 2017, https://doi.org/10.3923/ijp.2019.40.49
  15. High expression of HMBOX1 contributes to poor prognosis of gastric cancer by promoting cell proliferation and migration vol.115, pp.None, 2017, https://doi.org/10.1016/j.biopha.2019.108867
  16. Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer vol.25, pp.13, 2017, https://doi.org/10.1158/1078-0432.ccr-18-3789
  17. Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival vol.31, pp.1, 2017, https://doi.org/10.1186/s43046-019-0005-0
  18. HIF-1α, VEGF and Tumor Invasion and Metastasis vol.10, pp.5, 2017, https://doi.org/10.12677/acm.2020.105124
  19. HIF-1α, VEGF and Tumor Invasion and Metastasis vol.10, pp.5, 2017, https://doi.org/10.12677/acm.2020.105124
  20. Galectin-3 Interacts with C/EBPβ and Upregulates Hyaluronan-Mediated Motility Receptor Expression in Gastric Cancer vol.18, pp.3, 2017, https://doi.org/10.1158/1541-7786.mcr-19-0811
  21. Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis vol.21, pp.10, 2020, https://doi.org/10.3390/ijms21103686
  22. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies vol.21, pp.11, 2020, https://doi.org/10.3390/ijms21114012
  23. Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models vol.25, pp.11, 2017, https://doi.org/10.1111/jcmm.16362
  24. MiR-205–5p suppresses angiogenesis in gastric cancer by downregulating the expression of VEGFA and FGF1 vol.404, pp.2, 2017, https://doi.org/10.1016/j.yexcr.2021.112579
  25. Current and potential biomarkers in gastric cancer: a critical review of the literature vol.17, pp.25, 2017, https://doi.org/10.2217/fon-2021-0084
  26. Identification of stage-specific differentially expressed genes and SNPs in gastric cancer employing RNA-Seq based transcriptome profiling vol.114, pp.1, 2017, https://doi.org/10.1016/j.ygeno.2021.11.032